Dilated Cardiomyopathy Therapeutic Market Report

Global and Region Dilated Cardiomyopathy Therapeutic Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：218
  • REPORT CODE：GMM922372
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Dilated Cardiomyopathy Therapeutic market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Dilated Cardiomyopathy Therapeuticmarket, defines the market attractiveness level of Dilated Cardiomyopathy Therapeutic market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Dilated Cardiomyopathy Therapeutic industry, describes the types of Dilated Cardiomyopathy Therapeutic market, the applications of major players and the market size, and deeply analyzes the current situation of the global Dilated Cardiomyopathy Therapeutic market and the development prospects and opportunities of Dilated Cardiomyopathy Therapeutic industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Dilated Cardiomyopathy Therapeutic market in Chapter 13.

    By Player:

    • Merck & Co Inc

    • Pfizer Inc

    • Janssen Pharmaceuticals Inc (J&J)

    • Teva Pharmaceutical Industries Ltd

    • Vericel Corporation

    • Sanofi SA

    • GlaxoSmithKline plc

    • AstraZeneca plc

    • Novartis International AG

    • Array BioPharma Inc

    • Celladon Corporation

    By Type:

    • Aldosterone antagonists

    • Angiotensin-converting enzyme (ACE) inhibitors

    • Angiotensin II receptor blockers (ARBs)

    • Beta-blockers

    By End-User:

    • Hospitals

    • Academic Institutions

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Dilated Cardiomyopathy Therapeutic Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Dilated Cardiomyopathy Therapeutic Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Dilated Cardiomyopathy Therapeutic Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Dilated Cardiomyopathy Therapeutic Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Dilated Cardiomyopathy Therapeutic Market Analysis and Outlook to 2022

    • 7.1 Global Dilated Cardiomyopathy Therapeutic Consumption (2017-2022)

    • 7.2 United States Dilated Cardiomyopathy Therapeutic Consumption (2017-2022)

    • 7.3 Europe Dilated Cardiomyopathy Therapeutic Consumption (2017-2022)

    • 7.4 China Dilated Cardiomyopathy Therapeutic Consumption (2017-2022)

    • 7.5 Japan Dilated Cardiomyopathy Therapeutic Consumption (2017-2022)

    • 7.6 India Dilated Cardiomyopathy Therapeutic Consumption (2017-2022)

    • 7.7 South Korea Dilated Cardiomyopathy Therapeutic Consumption (2017-2022)

    8 Region and Country-wise Dilated Cardiomyopathy Therapeutic Market Analysis and Outlook to 2028

    • 8.1 Global Dilated Cardiomyopathy Therapeutic Consumption Forecast (2022-2028)

    • 8.2 United States Dilated Cardiomyopathy Therapeutic Consumption Forecast (2022-2028)

    • 8.3 Europe Dilated Cardiomyopathy Therapeutic Consumption Forecast (2022-2028)

    • 8.4 China Dilated Cardiomyopathy Therapeutic Consumption Forecast (2022-2028)

    • 8.5 Japan Dilated Cardiomyopathy Therapeutic Consumption Forecast (2022-2028)

    • 8.6 India Dilated Cardiomyopathy Therapeutic Consumption Forecast (2022-2028)

    • 8.7 South Korea Dilated Cardiomyopathy Therapeutic Consumption Forecast (2022-2028)

    9 Global Dilated Cardiomyopathy Therapeutic Market Outlook by Types and Applications to 2022

    • 9.1 Global Dilated Cardiomyopathy Therapeutic Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Aldosterone antagonists Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Angiotensin-converting enzyme (ACE) inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Angiotensin II receptor blockers (ARBs) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Beta-blockers Consumption and Growth Rate (2017-2022)

    • 9.2 Global Dilated Cardiomyopathy Therapeutic Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Academic Institutions Consumption and Growth Rate (2017-2022)

    10 Global Dilated Cardiomyopathy Therapeutic Market Outlook by Types and Applications to 2028

    • 10.1 Global Dilated Cardiomyopathy Therapeutic Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Aldosterone antagonists Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Angiotensin-converting enzyme (ACE) inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Angiotensin II receptor blockers (ARBs) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Beta-blockers Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Dilated Cardiomyopathy Therapeutic Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Academic Institutions Consumption Forecast and Growth Rate (2022-2028)

    11 Global Dilated Cardiomyopathy Therapeutic Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Dilated Cardiomyopathy Therapeutic Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Dilated Cardiomyopathy Therapeutic Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Dilated Cardiomyopathy Therapeutic Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Dilated Cardiomyopathy Therapeutic Market Competitive Analysis

    • 14.1 Merck & Co Inc

      • 14.1.1 Merck & Co Inc Company Details

      • 14.1.2 Merck & Co Inc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Merck & Co Inc Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.2 Pfizer Inc

      • 14.2.1 Pfizer Inc Company Details

      • 14.2.2 Pfizer Inc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Pfizer Inc Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.3 Janssen Pharmaceuticals Inc (J&J)

      • 14.3.1 Janssen Pharmaceuticals Inc (J&J) Company Details

      • 14.3.2 Janssen Pharmaceuticals Inc (J&J) Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Janssen Pharmaceuticals Inc (J&J) Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.4 Teva Pharmaceutical Industries Ltd

      • 14.4.1 Teva Pharmaceutical Industries Ltd Company Details

      • 14.4.2 Teva Pharmaceutical Industries Ltd Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Teva Pharmaceutical Industries Ltd Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.5 Vericel Corporation

      • 14.5.1 Vericel Corporation Company Details

      • 14.5.2 Vericel Corporation Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Vericel Corporation Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.6 Sanofi SA

      • 14.6.1 Sanofi SA Company Details

      • 14.6.2 Sanofi SA Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Sanofi SA Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.7 GlaxoSmithKline plc

      • 14.7.1 GlaxoSmithKline plc Company Details

      • 14.7.2 GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.8 AstraZeneca plc

      • 14.8.1 AstraZeneca plc Company Details

      • 14.8.2 AstraZeneca plc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 AstraZeneca plc Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.9 Novartis International AG

      • 14.9.1 Novartis International AG Company Details

      • 14.9.2 Novartis International AG Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Novartis International AG Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.10 Array BioPharma Inc

      • 14.10.1 Array BioPharma Inc Company Details

      • 14.10.2 Array BioPharma Inc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Array BioPharma Inc Dilated Cardiomyopathy Therapeutic Product and Service

    • 14.11 Celladon Corporation

      • 14.11.1 Celladon Corporation Company Details

      • 14.11.2 Celladon Corporation Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Celladon Corporation Dilated Cardiomyopathy Therapeutic Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Dilated Cardiomyopathy Therapeutic

    • Figure Dilated Cardiomyopathy Therapeutic Picture

    • Table Global Dilated Cardiomyopathy Therapeutic Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Dilated Cardiomyopathy Therapeutic Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Dilated Cardiomyopathy Therapeutic Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Dilated Cardiomyopathy Therapeutic Consumption by Country (2017-2022)

    • Figure United States Dilated Cardiomyopathy Therapeutic Consumption and Growth Rate (2017-2022)

    • Table Europe Dilated Cardiomyopathy Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure China Dilated Cardiomyopathy Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure Japan Dilated Cardiomyopathy Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure India Dilated Cardiomyopathy Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure South Korea Dilated Cardiomyopathy Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure Global Dilated Cardiomyopathy Therapeutic Consumption Forecast by Country (2022-2028)

    • Figure United States Dilated Cardiomyopathy Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Dilated Cardiomyopathy Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Dilated Cardiomyopathy Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Dilated Cardiomyopathy Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Dilated Cardiomyopathy Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Dilated Cardiomyopathy Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Aldosterone antagonists Consumption and Growth Rate (2017-2022)

    • Figure Global Angiotensin-converting enzyme (ACE) inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Angiotensin II receptor blockers (ARBs) Consumption and Growth Rate (2017-2022)

    • Figure Global Beta-blockers Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Academic Institutions Consumption and Growth Rate (2017-2022)

    • Figure Global Aldosterone antagonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Angiotensin-converting enzyme (ACE) inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Angiotensin II receptor blockers (ARBs) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Beta-blockers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Academic Institutions Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Dilated Cardiomyopathy Therapeutic Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Dilated Cardiomyopathy Therapeutic Export by Region (Top 5 Countries) (2017-2028)

    • Table Merck & Co Inc (Foundation Year, Company Profile and etc.)

    • Table Merck & Co Inc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co Inc Dilated Cardiomyopathy Therapeutic Product and Service

    • Table Pfizer Inc (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Dilated Cardiomyopathy Therapeutic Product and Service

    • Table Janssen Pharmaceuticals Inc (J&J) (Foundation Year, Company Profile and etc.)

    • Table Janssen Pharmaceuticals Inc (J&J) Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Janssen Pharmaceuticals Inc (J&J) Dilated Cardiomyopathy Therapeutic Product and Service

    • Table Teva Pharmaceutical Industries Ltd (Foundation Year, Company Profile and etc.)

    • Table Teva Pharmaceutical Industries Ltd Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceutical Industries Ltd Dilated Cardiomyopathy Therapeutic Product and Service

    • Table Vericel Corporation (Foundation Year, Company Profile and etc.)

    • Table Vericel Corporation Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vericel Corporation Dilated Cardiomyopathy Therapeutic Product and Service

    • Table Sanofi SA (Foundation Year, Company Profile and etc.)

    • Table Sanofi SA Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi SA Dilated Cardiomyopathy Therapeutic Product and Service

    • Table GlaxoSmithKline plc (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Product and Service

    • Table AstraZeneca plc (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca plc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca plc Dilated Cardiomyopathy Therapeutic Product and Service

    • Table Novartis International AG (Foundation Year, Company Profile and etc.)

    • Table Novartis International AG Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis International AG Dilated Cardiomyopathy Therapeutic Product and Service

    • Table Array BioPharma Inc (Foundation Year, Company Profile and etc.)

    • Table Array BioPharma Inc Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Array BioPharma Inc Dilated Cardiomyopathy Therapeutic Product and Service

    • Table Celladon Corporation (Foundation Year, Company Profile and etc.)

    • Table Celladon Corporation Dilated Cardiomyopathy Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celladon Corporation Dilated Cardiomyopathy Therapeutic Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US